Showing results (91-100 of 1,983) with videos related to

Sort By:
Pageof 199
The Lancet. Neurology|September 1, 2009
Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trialJörg Ederle, Leo H Bonati, Joanna Dobson, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
The Lancet. Neurology|August 15, 2009
Focal cortical dysplasia type II: biological features and clinical perspectivesSanjay M Sisodiya, Susanne Fauser, J Helen Cross, et al.
The Lancet. Neurology|August 15, 2009
Treatment of hyperkinetic movement disordersJoseph Jankovic
The Lancet. Neurology|August 15, 2009
Central post-stroke pain: clinical characteristics, pathophysiology, and managementHenriette Klit, Nanna B Finnerup, Troels S Jensen
The Lancet. Neurology|August 12, 2009
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-upLinda Douw, Martin Klein, Selene Saa Fagel, et al.
The Lancet. Neurology|March 15, 2011
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomesAlasdair J Coles, Edward Fox, Anton Vladic, et al.
The Lancet. Neurology|April 21, 2015
Neuroimaging in autism spectrum disorder: brain structure and function across the lifespanChristine Ecker, Susan Y Bookheimer, Declan G M Murphy
The Lancet. Neurology|August 21, 2021
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S Reich, Douglas L Arnold, Patrick Vermersch, et al.
Pageof 199